# Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study

> **NCT04536532** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 52 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** HEC121120 tablets
- **DRUG:** HEC121120 placebo tablets
- **DRUG:** entecavir tablets
- **DRUG:** entecavir placebo tablets

## Key facts

- **NCT ID:** NCT04536532
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-09
- **Primary completion:** 2023-03-12
- **Final completion:** 2023-03-12
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Company decision to discontinue trial
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536532, "Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04536532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*